Quadrichemotherapy for advanced ovarian carcinoma

A. Kessinger, J. F. Foley, H. M. Lemon

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


In an effort to improve the length and rate of objective responses in patients with advanced ovarian carcinoma, a combination of four drugs was administered. Vincristine (10 μg/kg intravenously weekly), actinomycin D (500 μg intravenously weekly), oral methotrexate (1.25 mg daily) and oral cyclophosphamide (50 mg daily) were given to 25 evaluable patients with FIGO Stage III and IV ovarian carcinoma. After 12 weeks the vincristine and methotrexate were discontinued; cyclophosphamide and methotrexate were continued until disease progression was evident. Objective responses occurred in 56% of the patients. Toxicity was minimal. Patients not previously treated with radiotherapy or chemotherapy had a higher complete response rate (30%) than patients previously treated (13.3%). Mean length of complete response was 10.6+ months. The 1 year survival rate of these patients was 69.5% and the 5 year rate 22.7%. While the results are encouraging, single agent chemotherapy with an alkylating agent produces similar responses.

Original languageEnglish (US)
Pages (from-to)134-136
Number of pages3
JournalObstetrics and gynecology
Issue number2
StatePublished - 1976
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Quadrichemotherapy for advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this